The latest developments across the GLP-1 landscape, from new drug approvals and clinical research to pricing changes and policy shifts. Stay informed on the updates that affect Ozempic, Wegovy, Mounjaro, and the wider category.
News & Updates
A wrongful death lawsuit filed against Ozempic's maker is drawing attention to GLP-1 medication risks and patient safety. If you're currently taking or considering a GLP-1 drug, here's what the growing litigation wave means for you, and what questions to ask your doctor before your next dose.
Some patients taking GLP-1 medications like Ozempic and Mounjaro report that side effects masked early cancer warning signs, delaying diagnosis. This article breaks down which symptoms overlap, what the research says, and how to protect yourself while staying on track with your weight loss goals.
Generic versions of semaglutide (the drug in Ozempic) are entering the conversation in a big way. Real patients who've seen dramatic results are cheering the shift. Here's what the arrival of generics could mean for your wallet and your access to treatment.
A new study finds that Ozempic produces meaningful weight loss in adults over 65, a group often left out of major clinical trials. Here is what older adults and their families should know about semaglutide's effectiveness, safety considerations, and practical next steps for getting started.
Amazon has started stocking oral semaglutide (Ozempic pills) at kiosks with same-day delivery options. This shift could change how patients access GLP-1 medications, but raises important questions about cost, safety, and what "oral Ozempic" actually is.
The FDA is moving to remove GLP-1 medications from the 503B Compounding Bulks List, a regulatory step that could significantly limit access to compounded versions of semaglutide and tirzepatide. This article explains what the 503B designation means, why it matters to patients, and what your options are going forward.
Eli Lilly's Mounjaro (tirzepatide) has surpassed Merck's Keytruda to become the world's top-selling drug, a milestone that signals a dramatic shift in how medicine treats obesity and type 2 diabetes. For patients researching GLP-1 medications, this news carries real implications for supply, pricing, and access. Here is what you need to know.
The FDA's recent action on compounded semaglutide is shaking up telehealth GLP-1 providers, and altRx is no exception. This review covers what altRx is offering in 2026, how their pricing and refund policy stack up, and what patients need to know before signing up or switching providers.
